A diagnostic pitfall in cold agglutinin disease: KMT2D-mutated CAD-associated lymphoproliferative disorder with a CLL-like immunophenotype
Authors:
Open Access
- 9 May 2026
- journal article
- Published by Oxford University Press (OUP) in Oxford Medical Case Reports
- Vol. 2026 (5)
Abstract
Cold agglutinin disease (CAD) is an uncommon hemolytic anemia by complement-fixing IgM autoantibodies and is frequently associated with a distinct clonal B-cell lymphoproliferative disorder (CAD-LPD). We report a woman in her 50’s with progressive fatigue who presented with hemolytic anemia and an IgM-κ paraprotein. Bone marrow examination revealed a small clonal B-cell population (5.8%) with a CLL-like immunophenotype. Despite the absence of peripheral lymphocytosis or established treatment indications for chronic lymphocytic leukemia (CLL), B-cell–directed therapy, including ibrutinib and venetoclax plus rituximab, was administered over the course of approximately one year based on the initial diagnostic impression, but failed to control hemolysis. Targeted next-generation sequencing identified a KMT2D frameshift mutation, supporting a diagnosis of CAD-LPD rather than monoclonal B-cell lymphocytosis. Subsequent treatment with the C1s inhibitor sutimlimab resulted in sustained resolution of hemolysis. This case highlights diagnostic pitfalls in CAD and underscores the value of molecular profiling in guiding appropriate therapy.Keywords
Funding Information
- Japan Agency for Medical Research and Development (23tk0124003h0001)
- Japan Agency for Medical Research and Development (JP19ck0106353h0003)
- Japan Society for the Promotion of Science (19H05656)
- Japan Society for the Promotion of Science (24H00009)
- Japan Society for the Promotion of Science (18H02836)
- FY2025 Kyoto University Hospital Research Fund for Young Scientists
This publication has 17 references indexed in Scilit:
- Sutimlimab in Cold Agglutinin DiseaseNew England Journal of Medicine, 2021
- How I treat cold agglutinin diseaseBlood, 2021
- High incidence of MYD88 and KMT2D mutations in Chinese with chronic lymphocytic leukemiaLeukemia, 2021
- Cold agglutinin disease revisited: a multinational, observational study of 232 patientsBlood, 2020
- Cold agglutinin disease: current challenges and future prospectsJournal of Blood Medicine, 2019
- A Randomized, First‐in‐Human, Healthy Volunteer Trial of sutimlimab, a Humanized Antibody for the Specific Inhibition of the Classical Complement PathwayClinical Pharmacology & Therapeutics, 2018
- Frequent somatic mutations of KMT2D (MLL2) and CARD11 genes in primary cold agglutinin diseaseBritish Journal of Haematology, 2017
- Mutations driving CLL and their evolution in progression and relapseNature, 2015
- Non-coding recurrent mutations in chronic lymphocytic leukaemiaNature, 2015
- Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphomaHaematologica, 2013